For the first time ever, a team of Toronto researchers are using a combination of ultrasound and blood tests to screen high-risk pregnant mothers for placental damage. By completing these non-invasive tests, most high-risk mothers can be reassured that their placenta is formed and functioning properly, so they can expect a healthy pregnancy. The tests are done early enough, at 16 to 23 weeks gestation, so if results are abnormal, physicians have time to improve pregnancy outcomes. “Close to 40 per cent of high-risk mothers we see in our clinic experience placental damage,” says Dr. John Kingdom, Principal Investigator of the study and Maternal-Fetal Medicine Specialist at Mount Sinai Hospital. The research is among the first to look at placenta health – a vital life line between mother and fetus through which nutrients, oxygen, antibodies and hormones pass.

“By identifying early on if there is a potential risk of complications, we can do everything possible to ensure the safety of both the mother and fetus,” says Dr. Kingdom, who is also a Professor in the Department of Obstetrics and Gynaecology at the University of Toronto. “We can reassure those with normal test results that their placentas are functioning well and they can expect a healthy pregnancy and birth.”

If the placenta is not functioning properly it could be a potential danger to the health of the mother and fetus. Abnormalities can lead to conditions such as preeclampsia, which is maternal high blood pressure, stillbirth or the need for a pre-term delivery.

The screening tests include: a maternal serum screening test used to detect Down’s syndrome, which measures the hormone levels in the mother’s blood; a uterine artery Doppler blood flow test, which checks the maternal blood flow in the placenta; and an ultrasound of the placental shape. Of the 212 high-risk women in the study, 19 delivered early due to poor fetal growth. None of these women had normal placental function test results. Likewise, only two of 22 stillbirths occurred in women with normal tests, and these losses were not related to abnormal placental function. This data demonstrates that the placenta screening tests can provide a good indication of which women may experience complications during pregnancy.

“This is an important first step in identifying placental abnormalities in early pregnancy, at a time when a number of interventions can be used to improve outcomes for those with the highest risk” says Dr. Kingdom. “This study will lead the way for future research in placenta screening and help us provide quality care for all mothers.”

###

The research will be published in the American Journal of Obstetrics and Gynecology in April 2007.

Mount Sinai Hospital

Mount Sinai Hospital is an internationally recognized, 472-bed acute care academic health centre, affiliated with the University of Toronto, known for the outstanding provision of compassionate patient care, innovative teaching and leading-edge research. Its Centres of Excellence include Women’s and Infants’ Health; Surgery and Oncology; Acute and Chronic Medicine; Laboratory Medicine and Infection Control; and the Samuel Lunenfeld Research Institute. For more information about Mount Sinai Hospital, please visit http://www.mtsinai.on.ca.

-For more information, please contact:

Jonathan MacIndoe
Mount Sinai Hospital
Tel: 416-586-4800 ext. 3815
Email: .(JavaScript must be enabled to view this email address)